_edited.jpg)
Genetic Testing and Personalized Treatment
Genetic testing identifies mutations such as BRCA1, BRCA2, and TP53, which increase ovarian cancer risk. NGS enables comprehensive profiling, guiding treatment decisions and preventive strategies.
The growing accessibility of genetic testing and the integration of results into clinical workflows are major drivers of the market. Personalized approaches in diagnostics are expected to improve early detection and survival rates.
Visit the Ovarian Cancer Diagnostics Market Size for detailed insights.
North America leads the ovarian cancer diagnostics market due to high healthcare expenditure, advanced medical infrastructure, and widespread awareness. Europe maintains steady growth with increasing adoption of novel diagnostics, while Asia-Pacific is rapidly expanding as healthcare access improves and awareness campaigns increase.